Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Sisällön tarjoaa Proactive Investors. Proactive Investors tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!
Siirry offline-tilaan Player FM avulla!
Theralase Technologies Announces Promising Preclinical Results for Ruvidar in Treating HSV-1
MP3•Jakson koti
Manage episode 437947205 series 2891889
Sisällön tarjoaa Proactive Investors. Proactive Investors tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share its lead drug formulation, Ruvidar, has shown significant preclinical effectiveness in destroying the Herpes Simplex Virus 1 (HSV-1), surpassing the current standard of care, Acyclovir. Acyclovir, widely used to manage HSV-1, does not cure the virus but helps to alleviate symptoms associated with herpes infections, such as cold sores, genital herpes, shingles, and chicken pox. DuMoulin-White highlighted that the global antiviral drug market is projected to reach around $71 billion by 2032, with approximately 3.7 billion people under age 50 infected with HSV-1. The preclinical findings indicate that Ruvidar is not only more potent than Acyclovir but also capable of preventing HSV-1 replication by an impressive 10 million-fold if administered one day post-infection—something Acyclovir fails to achieve. These promising results position Ruvidar as a potential game-changer in the treatment of HSV-1, offering hope for more effective management of this widespread virus. #proactiveinvestors #theralasetechnologiesinc #tsxv #tlt #otcqb #tftff #MedicalResearch #HealthcareInnovation #PatientCare #CancerResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #proactiveinvestors #theralasetechnologiesinc #tsxv #tlt #otcqb #tftff #MedicalResearch #HealthcareInnovation #PatientCare #CancerResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #Ruvidar #Acyclovir #Pharmaceuticals #Biotech #Oncology #ViralInfections #DrugDevelopment #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
617 jaksoa
MP3•Jakson koti
Manage episode 437947205 series 2891889
Sisällön tarjoaa Proactive Investors. Proactive Investors tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share its lead drug formulation, Ruvidar, has shown significant preclinical effectiveness in destroying the Herpes Simplex Virus 1 (HSV-1), surpassing the current standard of care, Acyclovir. Acyclovir, widely used to manage HSV-1, does not cure the virus but helps to alleviate symptoms associated with herpes infections, such as cold sores, genital herpes, shingles, and chicken pox. DuMoulin-White highlighted that the global antiviral drug market is projected to reach around $71 billion by 2032, with approximately 3.7 billion people under age 50 infected with HSV-1. The preclinical findings indicate that Ruvidar is not only more potent than Acyclovir but also capable of preventing HSV-1 replication by an impressive 10 million-fold if administered one day post-infection—something Acyclovir fails to achieve. These promising results position Ruvidar as a potential game-changer in the treatment of HSV-1, offering hope for more effective management of this widespread virus. #proactiveinvestors #theralasetechnologiesinc #tsxv #tlt #otcqb #tftff #MedicalResearch #HealthcareInnovation #PatientCare #CancerResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #proactiveinvestors #theralasetechnologiesinc #tsxv #tlt #otcqb #tftff #MedicalResearch #HealthcareInnovation #PatientCare #CancerResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #Ruvidar #Acyclovir #Pharmaceuticals #Biotech #Oncology #ViralInfections #DrugDevelopment #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
617 jaksoa
Kaikki jaksot
×Tervetuloa Player FM:n!
Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.